TY - JOUR
AB - MAP3K1 is a MAPK family serine‑threonine kinase that is frequently mutated in human cancer. The association between mutations in the MAP3K1 gene and the clinicopathological characteristics and prognosis of patients with breast cancer remain unclear in the Chinese population. Thus, the aim of the present retrospective study was to investigate the possible role and function of MAP3K1 in breast cancer. Data obtained from 412 consecutive patients with breast cancer were selected from Guangdong Provincial People's Hospital (GDPH) for analysis in the present study. Mutations were assessed using next‑generation sequencing. The association between MAP3K1 mutations and clinicopathological features were analyzed and further compared with the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) cohort and data from The Cancer Genome Atlas (TCGA). In the GDPH cohort, a total of 45 mutations MAP3K1 were identified in 8.5% (n=35) of the 412 patients, compared with 9.7% (n=244) in METABRIC and 7.9% (n=88) in TCGA. The majority of the mutations identified in the in three cohorts were truncating mutations, followed by mis‑sense mutations. Mutations in MAP3K1 were predominant in patients with the luminal A and B breast cancer subtypes in METABRIC datasets (P<0.001), although no significant differences were observed in the GDPH cohort (P=0.227). In the METABRIC cohort, patients with MAP3K1 mutations experienced a improved overall survival (OS) rate than patients without MAP3K1 mutations (P=0.006). In patient with hormone receptor (HR)+ breast cancer, a more significantly higher OS rate was observed in patients with MAP3K1 mutations (P<0.001). MAP3K1 expression was associated with OS in the HR+ subgroup. Moreover, the MAP3K1 methylation levels were reduced in primary breast cancer tissue, compared with normal tissue. Thus, the present findings identified MAP3K1 mutations in Chinese patients with breast cancer, and compared MAP3K1 mutations between the cohorts from Western and Eastern countries.
AD - Department of Breast Cancer, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong 510080, P.R. China
AU - Li,Cheukfai
AU - Zhang,Guochun
AU - Wang,Yulei
AU - Chen,Bo
AU - Li,Kai
AU - Cao,Li
AU - Ren,Chongyang
AU - Wen,Lingzhu
AU - Jia,Minghan
AU - Mok,Hsiaopei
AU - Lai,Jianguo
AU - Xiao,Weikai
AU - Li,Xuerui
AU - Liao,Ning
DA - 2022/02/01
DO - 10.3892/ol.2022.13187
IS - 2
JO - Oncol Lett
KW - breast cancer
MAP3K1 mutation
next‑generation sequencing
DNA methylation
PY - 2022
SN - 1792-1074
1792-1082
SP - 68
ST - Spectrum of MAP3K1 mutations in breast cancer is luminal subtype‑predominant and related to prognosis
T2 - Oncology Letters
TI - Spectrum of MAP3K1 mutations in breast cancer is luminal subtype‑predominant and related to prognosis
UR - https://doi.org/10.3892/ol.2022.13187
VL - 23
ER -